Codexis Unveils Notable Presentations at TIDES Event
Codexis, Inc. (NASDAQ: CDXS), recognized as a leading provider of enzymatic solutions, has announced its participation in the upcoming TIDES Europe annual meeting. This event, dedicated to innovations in RNA therapeutics, promises to showcase significant advancements in the field. Codexis will present three key data sessions that spotlight its proprietary ECO Synthesis™ manufacturing platform and its application in manufacturing small interfering RNA (siRNA).
Overview of Presentations at TIDES Europe
The conference, scheduled for November 12-14, will be held in Hamburg. Attendees are encouraged to connect with the Codexis team at Booth #709. The Company has a robust lineup of presentations that will delve into real-world applications of their cutting-edge technology.
Spotlight Presentation Details
Title: Process Development for Enzymatic Synthesis of RNAi Therapeutics
Presented by: Derek Gauntlett, Senior Director, ECO Synthesis Process Development
Date: November 14, 2024
Time: 1:25 pm – 1:55 pm CET
Additional Talks and Posters
TIDES Talk: RNA Synthesis Using Ligation for Improved Scalability and Reduced Manufacturing Cost
Presented by: Mathew Miller, PhD, Director of Life Science & RNA Technology
Date: November 13, 2024
Time: 3:55 pm – 4:10 pm CET
Also, Codexis will showcase a poster presentation on how engineered dsRNA ligases can efficiently enhance siRNA manufacturing during the conference.
The Rise of RNAi Therapeutics
The adoption of ribonucleic acid (RNA) as a potential treatment has significantly expanded in recent years, particularly with the success of messenger RNA (mRNA) vaccines and the advancement of siRNA candidates in clinical trials. This growth has revealed challenges in scaling up the production of RNA interference (RNAi) therapeutics using traditional manufacturing techniques. The industry is witnessing an influx of over 450 RNAi therapies in various developmental stages, with a notable number in latter-phase trials aimed at serious health conditions.
Impact of the ECO Synthesis Manufacturing Platform
Codexis' ECO Synthesis™ platform has been designed to mitigate the complexities associated with traditional RNAi therapeutic production. Recent presentations highlighted the successful enzymatic synthesis of lumasiran, a commercially available siRNA therapeutic, and also showcased impressive outcomes with shorter sequences involved in givosiran synthesis. The data from previous conferences indicate that Codexis has achieved coupling efficiencies exceeding 98%, mirroring the performance of established chemical synthesis methods, yet with a distinct reduction in the impurities typically seen.
About Codexis
Codexis is innovating within the realm of scalable and efficient therapeutics manufacturing through its proprietary CodeEvolver® technology platform. By focusing on enzymatic solutions, Codexis aims to resolve everyday challenges tied to small molecule pharmaceuticals and nucleic acid synthesis. Their commitment to developing the ECO Synthesis™ platform is driven by the belief that enzymatic manufacturing can provide significant advancements in yield, energy efficiency, and waste reduction in the production of RNAi therapeutics.
Frequently Asked Questions
What is the focus of Codexis' presentations at TIDES Europe?
Codexis will present on the innovative ECO Synthesis™ platform, showcasing advancements in siRNA manufacturing.
When does the TIDES Europe meeting take place?
The event is scheduled for November 12-14, 2024, in Hamburg, Germany.
What notable achievements has Codexis accomplished with its platform?
They have demonstrated coupling efficiencies greater than 98% in enzymatic synthesis, rivaling traditional methods.
Who will be presenting for Codexis?
Derek Gauntlett and Mathew Miller, among others, will lead discussions during the presentations.
How can attendees interact with Codexis at the conference?
Attendees can visit their booth #709 and schedule appointments in advance.
